Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are utilized in the treatment of T2DM and obesity, with agents such as semaglutide, albiglutide, dulaglutide, exenatide, liraglutide, and lixisenatide currently in use [139]. The gene discussed is GLP1R; the disease is obesity disorder.